<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03645603</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2015-002114-80 OsSC</org_study_id>
    <nct_id>NCT03645603</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Dexmedetomidine During Weaning From Analgesia and Sedation in PICU (TIP-15-01)</brief_title>
  <acronym>TIP-15-01</acronym>
  <official_title>Efficacy and Safety of Dexmedetomidine During Weaning From Analgesia and Sedation in Pediatric Intensive Care Unit. A Multicenter, Double-blind, Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Azienda Ospedaliero-Universitaria di Bologna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Ospedaliera di Padova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IRCCS Azienda Ospedaliero-Universitaria di Bologna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This interventional study evaluates the efficacy of dexmedetomidine during weaning from&#xD;
      analgesic and sedative drugs in reducing the occurrence of the withdrawal syndrome in PICU.&#xD;
      All enrolled patients will undergo the same weaning regimen one half will receive&#xD;
      dexmedetomidine while the other will receive a placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children admitted to PICU need of analgesic and sedative drugs. Prolonged treatment can lead&#xD;
      to undesirable effects as dependence and tolerance. Patients that have developed dependence&#xD;
      may develop the withdrawal syndrome (WS) during the analgesics and sedatives weaning process.&#xD;
&#xD;
      Withdrawal symptoms are due to central nervous system excitement, gastrointestinal&#xD;
      disturbance, and sympathetic system activation. The incidence of withdrawal syndrome is&#xD;
      variable between 17 and 57% a recent study reported an incidence of 64.6% of WS in Italian&#xD;
      PICUs. The prevention strategies are addressed to the restriction of drug exposure and to the&#xD;
      gradual tapering of infusion. However, these strategies have weak evidence of effectiveness.&#xD;
      In this study, the investigators hypothesize that dexmedetomidine may be useful and effective&#xD;
      during the weaning of analgosedation drugs in PICU, in preventing the withdrawal syndrome.&#xD;
      The primary aim of the study is to evaluate the efficacy of dexmedetomidine in reducing the&#xD;
      occurrence of the WS. Secondary aims are to evaluate the dexmedetomidine safety during the&#xD;
      weaning, the effective dose range, and the efficacy in reducing the duration of the weaning,&#xD;
      of the mechanical ventilation, and of the length of PICU stay. Efficacy will be compared&#xD;
      among pediatric age groups, gender, race, Pediatric Index of Mortality (PIM3) score, and&#xD;
      length of the analgosedation treatment.&#xD;
&#xD;
      Patients admitted to the PICU that meets the inclusion criteria, will be randomly assigned to&#xD;
      one of the two treatment groups: treatment A (dexmedetomidine) or treatment B (placebo).&#xD;
&#xD;
      Twenty-four hours before the start of the weaning an intravenous infusion of&#xD;
      dexmedetomidine/placebo will start. After 24 hours of dexmedetomidine infusion, the weaning&#xD;
      regimen will begin following the subsequent indications: 10% reduction of the dose every 12&#xD;
      hours. The withdrawal assessment tool version 1 (WAT-1) is the selected scale to evaluate the&#xD;
      occurrence of the WS. Patients with a score of WAT-1 &lt;3 continue the weaning regimen.&#xD;
      Patients with a score ≥3 increase the dose of dexmedetomidine/placebo until the next WAT-1&#xD;
      score control and temporarily stop the planned 10% dose reduction. If the next WAT-1 score&#xD;
      decreased by at least 1 point from the previous score, the weaning program restarted (10%&#xD;
      reduction) without further changes in the dose of dexmedetomidine/placebo until the&#xD;
      subsequent score. The 'acute withdrawal crisis' will be treated with a rescue dose of the&#xD;
      opioid and/or benzodiazepine in use repeatable until resolution of the crisis. Once&#xD;
      analgesics and sedatives weaning is complete, dexmedetomidine will gradually discontinue.&#xD;
      Five days after discharge from PICU, a follow-up visit will be performed.&#xD;
&#xD;
      The sample size estimate is 80 participants for each of the two groups for a total of 160&#xD;
      patients recruited within a period of two years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    futility reasons&#xD;
  </why_stopped>
  <start_date type="Actual">August 30, 2018</start_date>
  <completion_date type="Actual">January 18, 2020</completion_date>
  <primary_completion_date type="Actual">January 18, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Withdrawal Assessment Tool (WAT-1) scale</measure>
    <time_frame>time 0 start dexmedetomidine and every 12 hours post-start dexmedetomidine for 7 days</time_frame>
    <description>WAT-1 score recorded every 12 hours.The score ranges from 0 to 12, a score ≥3 indicates the presence of signs/symptoms of withdrawal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in heart rate</measure>
    <time_frame>0,1, 2, 12, 24 hours post-start dexmedetomidine and then every 12 hours for 7 days</time_frame>
    <description>changes in heart rate will be recorded when their value differs more than 20% by the patient's baseline values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic Blood Pressure</measure>
    <time_frame>0,1, 2, 12, 24 hours post-start dexmedetomidine and then every 12 hours for 7 days</time_frame>
    <description>changes in Systolic Blood Pressure will be recorded when their value differs more than 20% by the patient's baseline values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diastolic Blood Pressure</measure>
    <time_frame>0,1, 2, 12, 24 hours post-start dexmedetomidine and then every 12 hours for 7 days</time_frame>
    <description>changes in Diastolic Blood Pressure will be recorded when their value differs more than 20% by the patient's baseline values.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Opioid dose</measure>
    <time_frame>7 days</time_frame>
    <description>verification of adherence to weaning regimen</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Sedative dose</measure>
    <time_frame>7 days</time_frame>
    <description>verification of adherence to weaning regimen</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Withdrawal Syndrome</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine 100 mcg/ml concentrate solution. Continuous iv infusion. Start dose 0.4 mcg/kg/h, increases by 0.2 mcg/kg/h until 0.8 mcg/kg/h (half dose for neonates). If withdrawal symptoms appear the dose can be increased to a maximum of 1.4 mcg/Kg/h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>saline solution for IV infusion. The administration of infusion will follow the experimental drug.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>Dexdor, Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>intravenous infusion of physiological saline solution to mimic dexmedetomidine infusion</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>physiological saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Continuous analgesic and sedative endovenous treatment for at least 5 days&#xD;
&#xD;
          -  Invasive or non-invasive mechanical ventilation&#xD;
&#xD;
          -  Clinical conditions that allow by clinical judgment the start of analgosedation&#xD;
             weaning&#xD;
&#xD;
          -  Post-natal age ≥ 7 days and PMA beyond the 37 weeks&#xD;
&#xD;
          -  Written informed consent obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hemodynamic instability&#xD;
&#xD;
          -  Cardiac bundle-branch block of 2 or 3 degree&#xD;
&#xD;
          -  Hypersensitivity to the alpha-agonists&#xD;
&#xD;
          -  Persistent fever of unknown origin or sensitivity to malignant hyperthermia&#xD;
&#xD;
          -  Use of alpha-agonist (clonidine or dexmedetomidine) in the last 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria C. Mondardini, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Azienda Ospedaliero Universitaria di Bologna Policlinico S.Orsola-Malpighi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PICU Policlinico S.Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Amigoni A, Mondardini MC, Vittadello I, Zaglia F, Rossetti E, Vitale F, Ferrario S, Savron F, Coffaro G, Brugnaro L, Amato R, Wolfler A, Franck LS; Network of Paediatric Intensive Care Unit Study Group (TIPNet). Withdrawal Assessment Tool-1 Monitoring in PICU: A Multicenter Study on Iatrogenic Withdrawal Syndrome. Pediatr Crit Care Med. 2017 Feb;18(2):e86-e91. doi: 10.1097/PCC.0000000000001054.</citation>
    <PMID>28157809</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 17, 2018</study_first_submitted>
  <study_first_submitted_qc>August 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2018</study_first_posted>
  <last_update_submitted>October 30, 2021</last_update_submitted>
  <last_update_submitted_qc>October 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Azienda Ospedaliero-Universitaria di Bologna</investigator_affiliation>
    <investigator_full_name>Maria Cristina Mondardini</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>pediatrics</keyword>
  <keyword>dexmedetomidine</keyword>
  <keyword>analgesia</keyword>
  <keyword>sedation</keyword>
  <keyword>pediatric intensive care unit</keyword>
  <keyword>abstinence syndrome</keyword>
  <keyword>assessment tool</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance Withdrawal Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 18, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT03645603/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

